Spero Therapeutics, Inc. (28)
Browse by Contract Category
Contracts
-
Non-Employee Director Compensation Policy, as amended
(Filed With SEC on March 31, 2022)
-
Description of Registrants Securities
(Filed With SEC on March 31, 2022)
-
Security Agreement, dated September 29, 2021, by and between Spero Therapeutics, Inc. and HCR Collateral Management, LLC
(Filed With SEC on September 30, 2021)
-
Revenue Interest Financing Agreement, dated September 29, 2021, by and between Spero Therapeutics, Inc. and entities managed by HealthCare Royalty Management, LLC
(Filed With SEC on September 30, 2021)
-
License Agreement, dated June 30, 2021, by and between the Registrant and Pfizer Inc
(Filed With SEC on August 5, 2021)
-
Third Amendment to Lease Agreement, dated May 4, 2020, by and between the Registrant and U.S. REIF Central Plaza Massachusetts, LLC
(Filed With SEC on August 6, 2020)
-
Form of Restricted Stock Unit Agreement under the 2017 Stock Incentive Plan, as amended
(Filed With SEC on August 30, 2021)
-
Spero Therapeutics, Inc. 2017 Stock Incentive Plan, as amended
(Filed With SEC on August 18, 2021)
-
Share Purchase Agreement, dated June 30, 2021, by and between the Registrant and Pfizer Inc
(Filed With SEC on August 5, 2021)
-
Controlled Equity Offering Sales Agreement, dated March 11, 2021, by and between the Registrant and Cantor Fitzgerald & Co
(Filed With SEC on March 11, 2021)
-
Amended and Restated License Agreement, dated January 15, 2021, by and between the Registrant and Everest Medicines II Limited
(Filed With SEC on March 11, 2021)
-
Employment Agreement, dated November 6, 2020, by and between the Registrant and Tamara Joseph
(Filed With SEC on March 11, 2021)
-
Employment Agreement, dated December 9, 2020, by and between the Registrant and Satyavrat Shukla
(Filed With SEC on March 11, 2021)
-
Underwriting Agreement, dated September 10, 2020, between Spero Therapeutics, Inc. and Cowen and Company, LLC and Evercore Group, L.L.C., as representatives of the several...
(Filed With SEC on September 14, 2020)
-
Amended and Restated Employment Agreement, dated April 22, 2020, by and between the Registrant and Thomas Parr Jr., Ph.D
(Filed With SEC on August 6, 2020)
-
Form of Stock Option Agreement under the 2019 Inducement Equity Incentive Plan, as amended
(Filed With SEC on August 6, 2020)
-
2019 Inducement Equity Incentive Plan, as amended
(Filed With SEC on August 6, 2020)
-
Consulting Agreement, dated November 4, 2019, by and between the Registrant and Danforth Advisors, LLC
(Filed With SEC on May 8, 2020)
-
Consulting Agreement, dated April 18, 2019, by and between the Registrant and David P. Southwell
(Filed With SEC on March 16, 2020)
-
Employment Agreement, dated January 1, 2020, by and between the Registrant and Timothy Keutzer
(Filed With SEC on March 16, 2020)
-
Non-Employee Director Compensation Policy, as amended
(Filed With SEC on March 16, 2020)
-
Description of Registrants Securities
(Filed With SEC on March 16, 2020)
-
Investment Agreement, dated January 30, 2020
(Filed With SEC on January 30, 2020)
-
Securities Purchase Agreement, dated as of June 12, 2019, by and between Spero Therapeutics, Inc. and Novo Holdings A/S
(Filed With SEC on August 8, 2019)
-
Securities Purchase Agreement, dated as of June 12, 2019, by and between Spero Therapeutics, Inc. and Novo Holdings A/S
(Filed With SEC on June 13, 2019)
-
Form of Stock Option Agreement under the 2019 Inducement Equity Incentive Plan
(Filed With SEC on March 14, 2019)
-
License Agreement, dated January 4, 2019, by and between New Pharma License Holdings Limited and Everest Medicines II Limited
(Filed With SEC on March 14, 2019)
-
2019 Inducement Equity Incentive Plan
(Filed With SEC on March 14, 2019)